Wound complications frequency in heart transplant recipients on mammalian target of rapamycin inhibitors: A meta-analysis

Int Wound J. 2023 Nov;20(9):3491-3497. doi: 10.1111/iwj.14221. Epub 2023 May 10.

Abstract

A meta-analysis investigation was executed to measurethe wound complications (WCs) frequency in heart transplant (HT) recipients on mammalian target of rapamycin inhibitors (MTRIs). A comprehensive literature investigation till February 2023 was applied and 978 interrelated investigations were reviewed. The 10 chosen investigations enclosed 2173 individuals with HT were in the chosen investigations' starting point, 1164 of them were utilising MTRIs, and 1009 were utilising control. Odds ratio (OR) in addition to 95% confidence intervals (CIs) were utilised to compute the value of the WCs frequency in HT recipients on MTRIs by the dichotomous approaches and a fixed or random model. MTRIs had significantly higher WCs (OR, 1.53; 95% CI, 1.19-1.98, P = .001) compared with those with control in individuals with HT. MTRIs had significantly higher WCs compared with those with control in individuals with HT. However, care must be exercised when dealing with its values because of the low number of the nominated investigations and the low sample size of some of the nominated investigations for the meta-analysis.

Keywords: heart transplant; mammalian target of rapamycin inhibitors; surgical site wound infection; wound complication.

Publication types

  • Meta-Analysis

MeSH terms

  • Heart Transplantation* / adverse effects
  • Humans
  • Immunosuppressive Agents* / adverse effects
  • TOR Serine-Threonine Kinases

Substances

  • Immunosuppressive Agents
  • TOR Serine-Threonine Kinases